ArticleWorld journal of microbiology & biotechnology2026
Self-amplifying mRNA vaccine cocktail against Staphylococcus aureus: A multi-epitope immunoinformatics and structural simulation framework.
Article in World journal of microbiology & biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Staphylococcus aureus (S. aureus) remains a critical global public health threat, and the development of effective non-antibiotic prophylactic strategies is an urgent priority. To date, no licensed vaccine exists for the prevention of invasive S. aureus infections in humans. In the present study, a comprehensive multi-method pipeline was employed to design a bivalent self-amplifying mRNA (saRNA) vaccine cocktail targeting the ClfA, Hly, and SraP virulence antigens of S. aureus. An integrated framework combining immunoinformatics, structural bioinformatics, molecular simulations, and repository-curated experimental benchmark data was applied to delineate the immunodominant epitopic regions of each antigen, culminating in the rational design of two saRNA candidate vaccines, SaBVax807 and SaTVax876. Molecular docking and molecular dynamics simulations were subsequently performed to characterize and validate the binding interactions of both constructs with anti-S. aureus Fab fragment antibodies and human leukocyte antigen (HLA) alleles. Population coverage analysis for SaTVax876 was conducted across sixteen geographically diverse regions to evaluate global applicability. Each candidate vaccine was subjected to codon optimization to maximize translational efficiency in human host cells and rigorously evaluated for safety, stability, and immunogenic potential through a comprehensive assessment of allergenicity, antigenicity, autoimmune risk, physicochemical properties, toxicity profiles, and molecular interaction dynamics. Collectively, our findings demonstrate that the saRNA vaccine cocktail exhibits favorable safety, structural stability, and computationally predicted immunogenic profiles against S. aureus. This study establishes a comprehensive computational and in silico foundation supporting the capacity of these candidate vaccines to elicit broad anti-S. aureus immune responses, and provides a validated evidence base to guide subsequent preclinical and clinical investigations.
Indexed as
Identifiers
42479253What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.